First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Department of Preventive Medicine and Public Health, Keio University School of Medicine, Tokyo, Japan.
Diabetes Obes Metab. 2019 Sep;21(9):2174-2179. doi: 10.1111/dom.13770. Epub 2019 Jun 11.
The aim of this study was to evaluate the efficacy of canagliflozin in reducing the required insulin dose and the risk of hypoglycaemia in type 2 diabetes (T2D). This study was conducted in patients with T2D treated with insulin. They were randomly assigned to the control (n = 17) and canagliflozin (n = 17, plus 100 mg/day canagliflozin) groups. In both groups, a defined insulin dose adjustment protocol was applied to achieve the same level of glycaemic control. The change from baseline in daily insulin dose was significantly smaller in the canagliflozin group (3.9 units/day) than in the control group (13.4 units/day; P = 0.040). Low blood glucose index and predicted % of blood glucose (BG) <70 mg/dL, which are hypoglycaemia-related variables, worsened significantly in the control group but both remained unchanged in the canagliflozin group. The standard deviation for night-time BG levels improved significantly only in the canagliflozin group. Supplementation of insulin therapy with 100 mg canagliflozin in patients with T2D reduced the required insulin dose and hypoglycaemic risk and flattened night-time glycaemic fluctuations while maintaining the same level of glycaemic control.
这项研究的目的是评估卡格列净在降低 2 型糖尿病（T2D）患者胰岛素剂量需求和低血糖风险方面的疗效。该研究在接受胰岛素治疗的 T2D 患者中进行。他们被随机分配到对照组（n=17）和卡格列净组（n=17，加用 100mg/天卡格列净）。在两组中，均应用了明确的胰岛素剂量调整方案以达到相同的血糖控制水平。与对照组（13.4 单位/天）相比，卡格列净组的胰岛素日剂量变化显著更小（3.9 单位/天；P=0.040）。低血糖指数和预测的血糖（BG）<70mg/dL 比例，即与低血糖相关的变量，在对照组显著恶化，但在卡格列净组保持不变。只有在卡格列净组，夜间 BG 水平的标准差才显著改善。在 T2D 患者中，补充 100mg 卡格列净的胰岛素治疗可减少胰岛素剂量需求和低血糖风险，并使夜间血糖波动变平，同时保持相同的血糖控制水平。
